炎症性肠病中的肌肉减少症：回顾过去的工作以铺平未来的道路。
Sarcopenia in Inflammatory Bowel Diseases: Reviewing Past Work to Pave the Path for the Future.
作者信息
Faye Adam S, Khan Tasnin, Cautha Sandhya, Kochar Bharati
机构信息
Division of Gastroenterology, NYU Grossman School of Medicine, New York, NY.
Department of Population Health, NYU Grossman School of Medicine, New York, NY.
出版信息
Curr Treat Options Gastroenterol. 2022 Sep;20(3):250-260. doi: 10.1007/s11938-022-00389-8. Epub 2022 Jun 17.
PURPOSE OF THE REVIEW
Sarcopenia is the loss of muscle quantity and strength. It is highly prevalent in patients with inflammatory bowel disease (IBD) and is associated with periods of ongoing inflammation. This review will summarize the prior work in the field and highlight areas for future research.
RECENT FINDINGS
The presence of sarcopenia has been associated with adverse outcomes in different populations. Most recently, sarcopenia has been associated with adverse postoperative outcomes and an increased likelihood of surgery in IBD. Despite this, significant heterogeneity among these studies limits the ability to draw definitive conclusions.
SUMMARY
The importance of sarcopenia in inflammatory bowel disease (IBD) is only beginning to be recognized. Future studies assessing it utility both as a risk stratification tool and a modifiable factor in IBD are needed.
综述目的
肌肉减少症是肌肉量和力量的丧失。它在炎症性肠病（IBD）患者中非常普遍，并且与持续炎症期相关。本综述将总结该领域以前的工作，并突出未来研究的领域。
最新发现
肌肉减少症的存在与不同人群的不良结局相关。最近，肌肉减少症与IBD患者术后不良结局及手术可能性增加相关。尽管如此，这些研究之间存在显著异质性，限制了得出明确结论的能力。
总结
肌肉减少症在炎症性肠病（IBD）中的重要性才刚刚开始被认识。未来需要评估其作为IBD风险分层工具和可改变因素的效用的研究。
Zotero 插件